Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

Stopped Astra Zeneca notified Dr. Rita Basu that they will not manufacture new drug due to business reasons and study was stopped.

Conditions

• Non-alcoholic Fatty Liver Disease (NAFLD)
• Non-alcoholic Steatohepatitis (NASH)

Interventions

• DRUG: AZ compound
• OTHER: Placebo

Sponsor

University of Alabama at Birmingham

Collaborators

• [object Object]